1. Volk, H.D. et al. Diagnostic value of an immune monitoring program for the clinical management of immunosuppressed patients with septic complications. Clin. Transplant 3. 246–252 (1989).
2. Volk, H.D. et al. Alterations in function and phenotype of monocytes from patients with septic disease: Predictive value and new therapeutic strategies. in Host Defense Dysfunction in Trauma, Shock and Sepsis. (eds. Faist, E. and Meakins, J.L.) 246–271 (Springer-Verlag, Berlin-Heidelberg-New York, 1993).
3. Döcke, W.D. et al. Monocytic deactivation in fatal septic disease — Role of tumor necrosis factor-α and interleukin-10. in The Immune Consequences of Trauma, Shock and Sepsis — Mechanisms and Therapeutic Approaches. Vol.1, MOF, MODS and SIRS: Basic Mechanisms in Inflammation and Tissue Injury, (eds. Faist, E., Baue, A.E. & Schildberg, F.W.) 162–168 (Pabst Science Publishers, Lengerich, Germany, 1996).
4. Randow, F. Mechanism of endotoxin desensitization: Involvement of interleukin 10 and transforming growth factor beta. J. Exp. Med. 181, 1887–1892 (1995).
5. Beutler, B., Milsark, I.W. & Cerami, A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229, 869–871 (1985).